TRIAL OF MEMANTINE FOR THE TREATMENT OF PARKINSON'S

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 帕金森病(PD)的定义是其运动异常和相关的多巴胺能丢失，但它总是伴随着认知障碍[1]。帕金森病的早期阶段通常涉及选择性认知障碍，包括记忆、执行、注意力和视觉空间功能的特定缺陷。这些进展并没有得到很好的描述。然而，至少75%的帕金森病患者最终会出现严重的全球损害的认知缺陷，这些缺陷与皮质痴呆综合征的特征重叠；痴呆症的平均患病率从25%到40%不等。虽然大多数神经退行性疾病缺乏特定的对症治疗，但帕金森病的独特之处在于，针对其主要运动特征和频繁发生的精神障碍，有效的躯体治疗是可用的。然而，尽管帕金森病的认知缺陷会影响日常功能，是精神障碍的主要风险因素，但对于帕金森病的认知症状或其进展，还没有明确的治疗方法。因此，这项建议的目标是进行一项小规模的先导性研究，以确定美金刚的有效性和耐受性，美金刚是一种N-甲基-D-天冬氨酸(NMDA)受体拮抗剂，用于治疗帕金森病患者的认知障碍。美金刚(南门达)目前被FDA批准用于治疗阿尔茨海默病。美金刚是一种中等亲和力、非竞争性的N-甲基-D-天冬氨酸(NMDA)受体拮抗剂，可能对与帕金森病相关的痴呆患者有利。 这项研究的结果将被用来开发一项更大规模的美金刚安慰剂对照试验，如果合适，还将为设计其他可能治疗帕金森病认知功能障碍的临床试验提供参考。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Parkinson's disease (PD) is defined by its motor abnormalities and associated dopaminergic loss, but it is invariably accompanied by cognitive impairment (1). Early stages of PD often involve selective cognitive impairments, including specific deficits in memory, executive, attention, and visuospatial functions. The progression of these is not well characterized. However, at least 75% of patients with PD eventually develop severe and globally impairing cognitive deficits that overlap with features of a cortical dementia syndrome; the average prevalence of dementia ranges from 25-40%. Whereas most neurodegenerative disorders lack specific symptomatic treatments, PD is unique in that effective somatic therapies are available for its primary motor features as well as the frequently occurring psychiatric disturbances. Yet, even though cognitive deficits in PD affect everyday functioning and are a major risk factor for psychiatric disturbances, there are no definitive treatments for the cognitive symptoms in PD or their progression. Accordingly, the goal of this proposal is to conduct a small-scale pilot study to determine the effectiveness and tolerability of memantine, a N-methyl-D-aspartate (NMDA)-receptor antagonist for the treatment of cognitive impairment in patients with PD. Memantine (Namenda) is currently approved by the FDA for treatment of Alzheimer's disease. Memantine, a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, may be beneficial to patients with dementia in association with PD. Results of the study will be used to develop a larger placebo-controlled trial of memantine, if appropriate, as well as inform the design of other clinical trials on potential treatments for cognitive dysfunction in PD.